Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Qiagen N.V. (NY: QGEN )

42.98 +0.30 (+0.70%)
Official Closing Price Updated: 7:00 PM EDT, May 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,317,948
Open 43.39
Bid (Size) 41.66 (1)
Ask (Size) 46.34 (1)
Prev. Close 42.68
Today's Range 42.92 - 43.51
52wk Range 34.74 - 47.70
Shares Outstanding 227,985,334
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
QGEN Stock Earnings: Qiagen Beats EPS, Beats Revenue for Q1 2024
QGEN stock results show that Qiagen beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
US Stocks Kick Off The Week In The Green, Tesla Rockets On China's FSD Approval, Yen Rallies: What's Driving Markets Monday?
U.S. stocks kicked off the week on a positive note, with all major averages edging higher in anticipation of significant events including earnings reports from tech giants like Amazon.com Inc.... 
Via Benzinga

Performance

YTD
-1.53%
-1.53%
1 Month
+2.55%
+2.55%
3 Month
-1.22%
-1.22%
6 Month
+9.64%
+9.64%
1 Year
-6.65%
-6.65%

More News

Read More
US Stocks Set To Approach New Week With Caution Ahead Of Fed Meeting, Tech Earnings: Analyst Says 'Buy The Dip' Contingent On This Condition
Via Benzinga
Topics Economy
Exposures Interest Rates
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
Via Benzinga
Topics Stocks
Exposures US Equities
Earnings Scheduled For February 6, 2024
Via Benzinga
Earnings Preview: Qiagen
Via Benzinga
Goldman Sachs Upgrades Twist Bioscience, Says Express Genes Launch Will Drive Margin Expansion
Via Benzinga
Qiagen's Health Odyssey: Expanding In Riyadh And Partnering In Public Projects
Via Benzinga
Qiagen Has Steady Income And Defensive Growth Potential, Goldman Sachs Upgrades Stock
Via Benzinga
Where Qiagen Stands With Analysts
Via Benzinga
These Companies Helped The German DAX Index Hit Its All-time High
Via Talk Markets
Analyst Expectations for Qiagen's Future
Via Benzinga
Preview: Qiagen's Earnings
Via Benzinga
Analyst Expectations for Qiagen's Future
Via Benzinga
Diagnostic Firm Qiagen's Q3 Earnings: Analyst Says Annual Projections Attainable Despite Macro Trends
Via Benzinga
QIAGEN and Myriad Genetics partner to advance companion diagnostics development for cancer
From Myriad Genetics, Inc.
Via GlobeNewswire
Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year
Via Benzinga
Exposures COVID-19
Will Chart Analysts Notice Bad Omen on Qiagen's Chart
Via Benzinga
Earnings Scheduled For October 30, 2023
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Bio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing Agreement
From Bio-Rad Laboratories, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 12, 2023
Via Benzinga
The 3 Most Promising Biotech Stocks to Buy Now
Via InvestorPlace
QIAGEN Announces Form 20-F Annual Report Filing for 2022 Results
From QIAGEN N.V.
Via Business Wire
QIAGEN and Servier Partner to Develop Companion Diagnostic for Acute Myeloid Leukemia (AML) Therapy Drug
From QIAGEN N.V.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.